Lyme Disease Diagnosis Using Borrelia Antigen Mixtures
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tests for Lyme disease face challenges in sensitivity and specificity, often resulting in false-positive and false-negative results due to the lack of specific signs and symptoms, and the two-tiered testing approach recommended by the CDC still has limitations, leading to delayed treatment and potential serious complications.
Innovation Solution
The use of antigenic compositions comprising a mixture of Borrelia antigens, including BBA25 and BB0147 proteins, and hybrid peptides, which are capable of forming complexes with antibodies in a sample, allowing for the detection of anti-Borrelia antibodies through a detection moiety, thereby improving the accuracy of Lyme disease diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional ELISA and Western Blot tests are used for Lyme disease diagnosis, then the testing approach follows CDC recommendations, but the sensitivity and specificity remain insufficient leading to false-positive and false-negative results
Solution Approach 1:
The patent segments the Borrelia antigen into multiple distinct recombinant proteins (OspA, OspC, VlsE, BmpA, P66) and presents them separately in the assay. This segmentation allows for more specific antibody detection against individual antigens rather than a mixture, reducing cross-reactivity and improving diagnostic precision while maintaining reliability through multiple target antigens.
Solution Approach 2:
The patent uses a composite assay system that combines multiple recombinant Borrelia antigens expressed in E. coli, purified through a standardized protocol. This composite approach creates a multi-antigen panel that enhances both sensitivity (detecting more true positives) and specificity (reducing false positives) compared to single-antigen tests, thereby improving overall measurement precision without sacrificing reliability.
2Reliability
If the two-tiered testing approach is implemented, then CDC guidelines are followed, but treatment delay occurs due to inconclusive results
Solution Approach 1:
The patent performs preliminary enrichment of Borrelia antigens from patient samples using specific recombinant proteins before the main detection step. This preliminary action concentrates the target antigens and reduces background interference, enabling more definitive results in a single test rather than requiring sequential two-tiered testing, thus reducing diagnosis time while maintaining diagnostic consistency.
Solution Approach 2:
The patent introduces recombinant Borrelia antigens expressed in E. coli as intermediary targets that bridge the gap between patient antibodies and detection systems. These intermediaries provide highly specific binding targets that improve signal clarity, allowing for more conclusive single-step diagnosis rather than ambiguous results requiring follow-up testing, thereby reducing time loss without compromising reliability.
3Measurement precision
If standard serological testing is used, then antibody detection is performed, but insufficient Borrelia antigen presentation leads to false-negative results
Solution Approach 1:
The patent performs preliminary enrichment and concentration of Borrelia antigens from patient samples using immunomagnetic beads coated with recombinant antigens. This preliminary action increases the quantity of available antigen before the main detection step, ensuring sufficient target material for accurate antibody detection and reducing false-negative results while maintaining measurement precision.
Solution Approach 2:
The patent uses a composite approach combining multiple recombinant Borrelia antigens (OspA, OspC, VlsE, BmpA, P66) in the assay mixture. This composite material strategy increases the total quantity of diverse antigenic targets presented to patient antibodies, improving the likelihood of detecting true positive cases that might be missed by single-antigen tests, thereby enhancing measurement precision without sacrificing antigen quantity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described method enhances the sensitivity and specificity of Lyme disease diagnosis, reducing false-positive and false-negative results, and provides a more reliable means of detecting anti-Borrelia antibodies, potentially leading to earlier and more accurate treatment.
Implementation Method 1
each of the at least three capture moieties is capable of forming at least one complex with at least one antibody to the disease-causing agent in the sample
Implementation Method 2
the detection moiety binds to the antibody of the antibody-capture moiety complex
Data Source
AI summary
This disclosure provides antigen compositions useful for diagnosing Lyme disease and for detecting antibodies that bind to Borrelia antigens. The antigenic compositions comprise a mixture of hybrid peptides and Borrelia proteins. This disclosure also provides devices, methods, and kits that are useful for diagnosing Lyme disease and for detecting anti-Borrelia antibodies in a sample to aid in the diagnosis of Lyme disease.